Global Market for Sickle Cell Disease Treatment Poised to Expand at a Healthy CAGR of 6.0% During the Forecast Period 2017-2025 Global sickle cell disease treatment market is expected to witness robust growth during the forecast period. This growth is expected to be primarily driven by increasing adoption of therapies, growing awareness regarding the sickle cell disease treatment in MEA region. “Sickle Cell Disease Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)” is the new report published by Persistence Market Research for the projected period of 8-years, i.e. 2017-2025. According to this report, the global sickle cell disease treatment market is projected to expand at a CAGR of 6.0 % in terms of value during the forecast period to reach US$ 584.0 Mn by 2025. There is an increased opportunity of the development of the global sickle cell disease treatment market due to drug approvals and drugs in the pipeline which are expected to enter the market in the coming five years. On the basis of drug type, the global sickle cell disease treatment market is segmented into hydroxyurea, antibiotics, pain-relieving medications, and Others. The hydroxyurea segment is likely to be accounted for 38.7 % market revenue share in 2017, which is expected to increase to 35.7% by 2025 end. This drug type is expected to account for a high revenue contribution in the global sickle cell disease treatment market as compared to other drug types over the forecast period. Hydroxyurea product is expected to be the second attractive drug type segment in sickle cell disease treatment market, with market attractiveness index of 1.2. Request to view table of content @ https://www.persistencemarketresearch.com/marketresearch/sickle-cell-disease-treatment-market/toc On the basis of disease type, the global sickle cell disease treatment market is segmented into sickle cell anemia, sickle hemoglobin C disease, and sickle beta thalassemia. Sickle cell anemia is expected to be the most lucrative among all disease type segment of sickle cell disease treatment market, with attractiveness index of 1.8. Sickle Beta Thalassemia is expected to be the second attractive drug type segment in sickle cell disease treatment market, with market attractiveness index of 0.7. This segment include hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of drugs by governments to ensure availability in hospital pharmacies. Hospital pharmacies is expected to be the most lucrative among all distribution channels of sickle cell disease treatment market, with attractiveness index of 2.5. Retail pharmacies is expected to be the second largest distribution channels of sickle cell disease treatment market, with market attractiveness index of 0.4 A sample of this report is available upon request @ https://www.persistencemarketresearch.com/samples/16099 Five regions such as North America, Latin America, Europe, APAC and MEA are covered in this report. MEA regions are pegged to represent the most lucrative markets, owing to the high prevalent cases of sickle cell diseases. The MEA sickle cell disease treatment market is expected to expand at a CAGR of 6.1 % in terms of value over the forecast period. Growing awareness and adoption of treatment for sickle cell disease in India and in the APAC region is expected to create a sizeable opportunity for the players in this market. These are the key players in the global sickle cell disease treatment market- AstraZeneca Plc., Eli Lilly and Company, Eli Lilly and Company, Novartis AG, Pfizer Inc., Baxter International Inc., Emmaus Life Sciences, Inc., Bluebird bio, Inc., Global Blood Therapeutics Inc., Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Arena Pharmaceuticals, Inc., and Alnylam Pharmaceuticals, Inc. Browse Complete Report @ https://www.persistencemarketresearch.com/market-research/sicklecell-disease-treatment-market.asp About Us: Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multidimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes. Our offerings include pre-built reports that address every major sale, customized solutions to cater to client-specific needs, and consulting services to offer more value addition. Our next-generation research approach for exploring emerging technologies has allowed us to solve the most complex problems of clients. We do not follow a reactive approach, but a pro-active one. Expert analysts at PMR keep a tab on nextgeneration technologies in their R&D phase and provide the latest insights into these technologies when they are being commercialized. Our ground-breaking approach allows us to deliver market solutions before the technologies reach the market. Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset. Contact Us: Persistence Market Research 305 Broadway,7th Floor New York City, NY 10007 United States Tel: +1-646-568-7751 Email: [email protected] Website: http://www.persistencemarketresearch.com/ [email protected]
On the basis of disease type, the global sickle cell disease treatment market is segmented into sickle cell anemia, sickle hemoglobin C disease, and sickle beta thalassemia. Sickle cell anemia is expected to be the most lucrative among all disease
© Copyright 2024 Paperzz
